PVR and neoplasm: The antitumor mechanisms of VSRIPO include the following: (1) the direct infection and killing of CD155-expressing tumor cells and (2) the infection of intratumoral antigen-presenting cells, which activates innate and adaptive antitumor immune responses and releases inflammatory cascades leading to persistent systemic antitumor immunity [58].